Loading...
•
Mar 31, 2022
Veracyte Q1 2022 Earnings Report
Veracyte's first quarter results for 2022 showed strong revenue growth and progress in strategic initiatives.
Key Takeaways
Veracyte reported an 85% increase in total revenue to $67.8 million for the first quarter of 2022, driven by strong performance in testing revenue and the contribution of the HalioDx acquisition.
Total revenue increased by 85% to $67.8 million compared to the first quarter of 2021.
Test volumes grew to 23,245, a 61% increase compared to the first quarter of 2021.
Veracyte highlighted new data presentations at upcoming conferences for the Percepta Nasal Swab test and Decipher GRID database.
The Veracyte Biopharma Atlas, a pan-cancer database of biomarkers linked to clinical outcome data, was introduced at the American Association for Cancer Research annual meeting.
Revenue by Segment
Forward Guidance
The company is currently projecting full year 2022 total revenue of $265 million to $275 million, representing year-over-year growth of 21% to 25% compared to the prior year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...